ReN 1820
Alternative Names: TrkAd5Latest Information Update: 21 Jul 2006
Price :
$50 *
At a glance
- Originator University of Bristol
- Developer ReNeuron
- Class Anti-inflammatories
- Mechanism of Action Nerve growth factor inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Inflammation; Interstitial cystitis
Most Recent Events
- 21 Jul 2006 ReN 1820 is available for outlicensing (http://www.reneuron.com)
- 21 Jul 2006 Discontinued - Preclinical for Inflammation in United Kingdom (unspecified route)
- 21 Jul 2006 Discontinued - Preclinical for Interstitial cystitis in United Kingdom (unspecified route)